

Supplemental Table for:
Genomic classifier (ColoPrint) predicts recurrence of stage II colorectal cancer patients more accurately than clinical factors
Scott Kopetz et al.

Table S1. Patient information by hospital.

Variable	Total		ICO		Munich		VHB		Ferrara		MDA		p-value	
	N=416	%	n=115	27.6%	n=135	32.5%	n=50	12.0%	n=20	4.8%	n=96	23.1%		
Median Age	67.0		69.0		65.0		75.5		70.0		65.1		0.004	
Age > 65	No	171	41.1	39	33.9	66	48.9	14	28.0	4	20.0	48	50.0	0.003
	Yes	245	58.9	76	66.1	69	51.1	36	72.0	16	80.0	48	50.0	
Localization	L	206	49.5	60	52.2	78	57.8	22	44.0	6	30.0	40	41.7	0.002
	R	179	73.0	41	35.7	57	42.2	22	44.0	11	55.0	48	50.0	
	RE	31	7.5	14	12.2	0	0.0	6	12.0	3	15.0	8	8.3	
Grade	1	80	19.2	69	60.0	1	0.7	7	14.0	1	5.0	2	2.1	<0.001
	2	273	65.6	42	36.5	93	68.9	34	68.0	18	90.0	86	89.6	
	3	63	15.1	4	3.5	42	30.4	9	18.0	1	5.0	8	8.3	
Gender	M	243	58.4	72	62.6	77	57.0	25	50.0	12	60.0	57	59.4	0.653
	F	173	41.6	43	37.4	58	43.0	35	50.0	8	40.0	39	40.6	
Median LN assessed	19.0		18.0		20.0		16.0		15.5		20.5		0.006	
LN > 12	No	85	20.4	31	27.0	14	10.4	18	36.0	7	35.0	15	15.6	<0.001
	Yes	331	79.6	84	73.0	121	89.6	32	64.0	13	65.0	81	84.4	
pT	3	368	88.5	104	90.4	115	85.2	47	94.0	17	85.0	85	88.5	0.463
	4	48	11.5	11	9.6	20	14.8	3	6.0	3	15.0	11	11.5	
Therapy	No	292	70.2	74	64.3	128	94.8	18	36.0	11	55.0	61	63.5	<0.001
	Yes	124	29.8	41	35.7	7	5.2	32	64.0	9	45.0	35	36.5	
MSI status	MSS	336	80.8	102	88.7	102	75.6	38	76.0	17	85.0	77	80.2	0.092
	MSI	80	19.2	13	11.3	33	24.4	12	24.0	3	15.0	19	19.8	
NCCN	Low Risk	236	56.7	73	63.5	84	62.2	31	62.0	8	40.0	40	41.7	0.004
	High Risk	180	43.3	42	36.5	51	37.8	19	38.0	12	60.0	56	58.3	

ICO: Institut Català d'Oncologia. Barcelona, Spain; Munich: Klinikum Rechts der Isar, Technische University, Munich, Germany; VHB: Vall D'Hebron Hospital. Barcelona, Spain; Ferrara: University of Ferrara, Ferrara, Italy; MDA: University of Texas, MD Anderson Cancer Center. Houston, TX;